ABC | Volume 111, Nº5, Novembro 2018

Artigo Original Souza et al Rigidez Arterial e Toxicidade Cardiovascular Arq Bras Cardiol. 2018; 111(5):721-728 1. Fayer VA, Guerra MR, Cintra JR, Bustamante-Teixeira MT. Ten-year survival and prognostic factors for breast cancer in the southeast region of Brazil. Rev Bras Epidemiol. 2016;19(4):766-78. 2. Wu AH. Cardiotoxic drugs: clinical monitoring and decisionmaking. Heart. 2008;94(11):1503-9. 3. Chaosuwannakit N, D’Agostino R, Hamilton CA, Lane KS, Ntim WO, Lawrence J, et al. Aortic stiffness increases upon receipt of anthracycline chemotherapy. J Clin Oncol. 2010;28(1):166-72. 4. Koelwyn GJ, Lewis NC, Ellard SL, Jones LW, Gelinas JC, Rolf JD, et al. Ventricular-arterial coupling in breast cancer patients after treatment with anthracycline-containing adjuvant chemotherapy. Oncologist. 2016;21(2):141-9. 5. Mozos I, Borzak G, Caraba A, Mihaescu R. Arterial stiffness in hematologic malignancies. Onco Targets Ther. 2017 Mar 3;10:1381-8. 6. Brasil. Ministerio da Saúde. Diretrizes diagnosticas e terapeuticas do carcinoma de mama. Brasília; 2018. p.38. 7. Kalil Filho R, Hajjar LA, Bacal F, Hoff PM, Diz MeP, Galas FR, et al; Grupo de Estudos em Insuficiência Cardíaca da Sociedade Brasileira de Cardiologia (GEIC/SBC); Sociedade Brasileira deOncologia Clínica; Instituto doCoração – Faculdade deMedicina daUniversidade de São Paulo; Instituto doCâncer do Estado de São Paulo – Faculdade de Medicina da Universidade de São Paulo. [I BrazilianGuideline for Cardio-Oncology fromSociedade Brasileira de Cardiologia]. Arq Bras Cardiol. 2011;96(2 Suppl 1):1-52. 8. Chang HM, Okwuosa TM, Scarabelli T, Moudgil R, Yeh ET. Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: part 2. J Am Coll Cardiol. 2017;70(20):2552-65. 9. Mikael LR, Paiva AM, Gomes MM, Sousa AL, Jardim PC, Vitorino PV, et al. Vascular aging and arterial stiffness. Arq Bras Cardiol. 2017;109(3):253-8. 10. Erbel R, Aboyans V, Boileau C, Bossone E, Bartolomeo RD, Eggebrecht H, et al; ESC Committee for Practice Guidelines. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: Document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(41):2873-926. 11. Drafts BC, Twomley KM, D’Agostino R, Lawrence J, Avis N, Ellis LR, et al. Low tomoderate dose anthracycline-based chemotherapy is associatedwith early noninvasive imaging evidence of subclinical cardiovascular disease. JACC Cardiovasc Imaging. 2013;6(8):877-85. 12. Jones LM, Stoner L, Brown C, Baldi C, McLaren B. Cardiovascular disease among breast cancer survivors: the call for a clinical vascular health toolbox. Breast Cancer Res Treat. 2013;142(3):645-53. 13. Franssen PM, Imholz BP. Evaluation of the Mobil-O-Graph new generation ABPMdevice using the ESHcriteria. Blood PressMonit. 2010;15(4):229-31. 14. Campos Filho O, Zielinsky P, Ortiz J, Maciel BC, Andrade JL, Mathias W Jr, et al; Brazilian Society of Cardiology. [Guideline for indication and utilization of echocardiography in clinical practice]. Arq Bras Cardiol. 2004;82 Suppl 2:11-34. 15. Bönner F, Fenk R, Kochanek M, Pfister R. [2016 ESC position paper on cancer treatments and cardiovascular toxicity]. Dtsch Med Wochenschr. 2017;142(24):1826-30. 16. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer. 1973;32(2):302-14. 17. VonHoff DD, LayardMW, Basa P, Davis HL, VonHoff AL, RozencweigM, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91(5):710-7. 18. Santos GW, Sensenbrenner LL, Burke PJ, Mullins GM, Blas WB, Tutschka PJ, et al. The use of cyclophosphamide for clinical marrow transplantation. Transplant Proc. 1972;4(4):559-64. 19. Mizuno Y, Fuchikami H, Takeda N, Iwai M, Sato K. Efficacy of reduced dose of pegfilgrastim in Japanese breast cancer patients receiving dose- dense doxorubicin and cyclophosphamide therapy. Jpn J Clin Oncol. 2017;47(1):12-7. 20. Shulman LN, Berry DA, Cirrincione CT, Becker HP, Perez EA, O’Regan R, et al. Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer inwomenwith 0 to 3 positive axillary nodes: CALGB 40101 (Alliance). J ClinOncol. 2014;32(22):2311-7. 21. Procter M, Suter TM, de Azambuja E, Dafni U, van Dooren V, Muehlbauer S, et al. Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. J Clin Oncol. 2010;28(21):3422-8. 22. Muss HB, Berry DL, Cirrincione C, Theodoulou M, Mauer A, Cohen H, et al. Standard chemotherapy (CMF or AC) versus capecitabine in early-stage breast cancer (BC) patients aged 65 and older: results of CALGB/CTSU 49907. J Clin Oncol. 2008;26(15_suppl):507. 23. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442. 24. Lancellotti P, Anker SD, Donal E, Edvardsen T, Popescu BA, Farmakis D, et al. EACVI/HFACardiacOncology Toxicity Registry in breast cancer patients: rationale, study design, and methodology (EACVI/HFA COT Registry)-- EURObservational Research Programof the European Society of Cardiology. Eur Heart J Cardiovasc Imaging. 2015;16(5):466-70. 25. Cadeddu C, Mercurio V, Spallarossa P, Nodari S, Triggiani M, Monte I, et al. Preventing antiblastic drug-related cardiomyopathy: old and new therapeutic strategies. J Cardiovasc Med (Hagerstown). 2016 May;17 Suppl 1:S64-75. 26. Schmitz KH, Prosnitz RG, Schwartz AL, Carver JR. Prospective surveillance and management of cardiac toxicity and health in breast cancer survivors. Cancer. 2012;118(8 Suppl):2270-6. 27. A.VelásquezC,GonzálezM,MejíaM, JaramilloN.Cardiotoxicidad inducida por la quimioterapia desde las bases moleculares hasta la perspectiva clínica 2015. Rev Colomb Cardiol. 2016;23(2):104-11. 28. Skrypnyk I, Maslova G, Lymanets T, Gusachenko I. L-arginine is an effective medication for prevention of endothelial dysfunction, a predictor of anthracycline cardiotoxicity in patients with acute leukemia. Exp Oncol. 2017;39(4):308-11. 29. Herceg-Cavrak V, Ahel V, Batinica M, Matec L, Kardos D. Increased arterial stiffness in children treated with anthracyclines for malignant disease. Coll Antropol. 2011;35(2):389-95. 30. Finkelman BS, Putt M, Wang T, Wang L, Narayan H, Domchek S, et al. Arginine-nitric oxide metabolites and cardiac dysfunction in patients with breast cancer. J Am Coll Cardiol. 2017;70(2):152-62. 31. Krystal JI, Reppucci M, Mayr T, Fish JD, Sethna C. Arterial stiffness in childhood cancer survivors. Pediatr Blood Cancer. 2015;62(10):1832-7. 32. Fraeman KH, Nordstrom BL, Luo W, Landis SH, Shantakumar S. Incidence of new-onset hypertension in cancer patients: a retrospective cohort study. Int J Hypertens. 2013;2013:379252. 33. Okur A, Karadeniz C, ÖzhanOktar S, Pınarlı FG, Aral A, Oğuz A. Assessment of brachial artery reactivity, carotid intima-media thickness, and adhesion molecules in pediatric solid tumor patients treated with anthracyclines. Pediatr Hematol Oncol. 2016;33(3):178-85. 34. Belham M, Kruger A, Mepham S, Faganello G, Pritchard C. Monitoring left ventricular function in adults receiving anthracycline-containing chemotherapy. Eur J Heart Fail. 2007;9(4):409-14. 35. Gulati G, Zhang KW, Scherrer-Crosbie M, Ky B. Cancer and cardiovascular disease: the use of novel echocardiographymeasures to predict subsequent cardiotoxicity in breast cancer treatedwith anthracyclines and trastuzumab. Curr Heart Fail Rep. 2014;11(4):366-73. Referências 727